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The inability of Adeno-Associated Virus (AAV) to replicate on its own is a strong argument in favor of
the use of recombinant AAV vectors for in vivo gene transfer. However, some previous studies suggested
that AAV may become replication competent in cells exposed to a genotoxic stress even in the absence
of co-infection with a helper virus. To comprehensively explore this phenomenon, we examined AAV
genome replication in several human cell lines exposed to different genotoxic conditions. We found
that all treatments induced only negligible levels of AAV replication never exceeding ten fold above
background. Further investigation indicated that induction of helper-independent AAV replication
relied on the synergistic contribution of several extrinsic factors linked to the origin of the cell line and
the quality of the AAV preparation. These results further support the notion that helper independent
AAV replication cannot occur at signiﬁcant levels in vivo.
& 2012 Elsevier Inc. All rights reserved.Introduction
Recombinant vectors derived from the Adeno-Associated Virus
(rAAV) are currently considered as safe and efﬁcient tools for
in vivo gene transfer. One of the main safety concerns when using
viral vectors in gene therapy is possible mobilization in vivo
following complementation with functions provided by a wild-
type (wt) virus. This concern is of particular interest in the case of
AAV. Indeed, the wt virus is found in a variety of human tissues in
a latent state (Flotte and Berns, 2005). In addition, although AAV
is classiﬁed as a defective parvovirus that requires helper virus
for replication and progeny production, a variety of factors
and/or conditions have been suggested to possess the potential
to substitute helper virus functions and potentially assist AAV
replication. Consequently the identiﬁcation of factors allowing wt
AAV replication is essential to deﬁne conditions that could induce
uncontrolled rAAV replication and spreading of particles.
AAV particles are made up of a non-enveloped icosahedral
capsid that protects a single-stranded (ss) DNA genome of 4.7 kb.
The viral genome contains two genes, rep and cap, surrounded by
inverted terminal repeats (ITRs), which are the only sequencesll rights reserved.
yon, 46 Alle´e d’Italie, Lyon
etti).required in cis for genome replication and packaging. The rep gene
encodes four non-structural proteins, Rep78, 68, 52, and 40. The
two larger isoforms, Rep78 and 68, have DNA binding, helicase,
and site-speciﬁc endonuclease activities and are involved in AAV
gene expression and genome processing, including replication
and site-speciﬁc integration (Muzyczka and Berns, 2001). The two
smaller Rep isoforms are not required for AAV DNA replication
but are involved in the control of viral gene expression and
packaging of viral DNA (King et al., 2001). The cap gene encodes
in one frame the three isoforms of the capsid proteins and in
another frame a small protein, AAP, that is involved in capsid
assembly (Sonntag et al., 2010).
During AAV infection, the capsids deliver viral genomes to the
nucleus where they are converted to a double-stranded (ds),
transcription-competent DNA form. Studies conducted with rAAV
vectors have suggested that this process may result either from
annealing of ss genome strands of opposite polarity or second-
strand synthesis (Fisher et al., 1996; Hauck et al., 2004; Zhong
et al., 2008). Importantly, infection of cells by wt AAV alone is not
followed by any signiﬁcant virus genome replication beyond
eventual second-strand synthesis. Instead, it is followed by rapid
viral gene repression and establishment of viral latency, during
which ds viral genomes persist either as circular episomes or
integrated in the host cell DNA (Hauck et al., 2009). Co-infection
of cells with wt AAV and one of its several helper viruses allows
AAV genome replication to start. The viral Rep proteins are
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cellular DNA replication activities to the AAV origin of replication.
Interestingly, the viruses that can function as helpers for wt AAV
are very diverse. They include adenoviruses (Ad), herpes viruses
among which herpes simplex virus type 1 and 2 (HSV-1 and -2),
as well as papillomaviruses (HPV) (Geoffroy and Salvetti, 2005).
The poliomavirus SV40 has also been described as having at least
a partial helper effect by stimulating rep gene expression (Batchu
et al., 2001, 2002). However, the precise involvement of each of
these viruses in the in vivo life cycle of AAV remains unclear.
Despite the general requirement of a helper virus for wt
AAV replication, older studies have reported that detectable AAV
replication could occur in cells exposed to a variety of genotoxic or
cytostatic conditions. These included notably a genotoxic stress
induced by chemicals (MNNG, N-AAAF or 4-NQO) or irradiation
(UV-C) and induction of reversible cell cycle arrest by hydro-
xyurea, aphidicolin, reversion of polyamine depletion, and mitotic
detachment (Yakobson et al., 1987, 1989; Yalkinoglu et al., 1988).
Most of these studies were performed on transformed cell lines
and it was not excluded that transformation, whether virally
induced or not, may contribute to this phenomenon. Later studies
showed that similar treatments also stimulated rAAV transduction
probably by inducing second-strand synthesis (Alexander et al.,
1994; Cervelli et al., 2008; Russell et al., 1995; Zentilin et al.,
2001). As second-strand synthesis also represents the ﬁrst step
occurring during wt AAV genome replication, these latter studies
indirectly further supported the notion that helper independent
AAV could eventually replicate and accomplish its life cycle in the
absence of a helper virus.
In this study, we sought to comprehensively analyze wt
AAV helper-independent replication in response to a range of
genotoxic treatments. Surprisingly, the precise quantiﬁcation of
this phenomenon, never performed so far, indicated that only
minor levels of helper-independent AAV replication occurred in
response to a variety of treatments including hydroxyurea, one of
the best described inducers of helper-independent AAV replica-
tion. Further investigation revealed that at least two factors might
have contributed to the previously observed helper-independent
AAV replication: ﬁrst the presence of the SV40 LTAg in some of
the cell lines tested and second the quality of the AAV preparation
and, in particular, the presence of Ad-derived contaminants.
These results indicate that, at least in vitro, DNA damage and/or
cell cycle alterations result in very limited helper independent
AAV replication, and that induction beyond background levels
depends on the synergistic contribution of several extrinsic
factors.Fig. 1. Effect of genotoxic treatments on Rep protein synthesis. Cells were pre-
treated with each genotoxic agent and infected with either AAV (HeLa, MRC5, and
GM847) or AAVtR (U2OS) at an MOI of 103 gp/cell. Rep proteins were analyzed
48 h later by Western blot using the anti-Rep 303.9 antibody. Membranes were
then stripped and re-probed with an anti-tubulin antibody. In the case of cells co-
infected with wt HSV-1, analysis was performed 24 h post-infection. Note that a
lower level of tubulin, due to virus-induced shut off of host cell protein synthesis,
is frequently observed in HSV-1 infected cells (see also Fig. 5C).Results
Induction of AAV Rep protein synthesis in cells pretreated with
genotoxic agents
Because Rep protein synthesis is a pre-requisite for AAV
genome replication, we ﬁrst examined the capacity of a variety a
genotoxic treatments to induce rep gene expression in wt AAV-
infected cells. In particular, four treatments previously described to
enhance cell transduction by rAAV vectors were tested: etoposide
(Eto), an inhibitor of type II topoisomerases, that induces ds DNA
breaks (DSBs) (Russell et al., 1995); mitomycine C (MMC), that
induces inter- and intra-DNA strand cross-links and secondarily
some DSBs (Zentilin et al., 2001); hydroxyurea (HU), an inhibitor of
the nucleotide reductase enzyme, that induces replicative stress
and was previously reported to induce helper-independent AAV
replication in four cell lines (Cervelli et al., 2008; Ferrari et al., 1996;
Johnson and Samulski, 2009; Ju et al., 2004; Russell et al., 1995;Sanlioglu and Engelhardt, 1999; Teramoto et al., 1998; Yakobson
et al., 1987; Zentilin et al., 2001); and ionizing radiations (IR), that
have very large effects, including induction of DSBs (Alexander
et al., 1994, 1996). As a positive control, cells were co-infected with
wt HSV-1 to provide helper activities. To sample a variety of cellular
environments, such treatments were tested on primary (MRC5),
spontaneously transformed (U2OS) and virus-transformed (HeLa
and GM847, transformed by HPV18 and SV40, respectively) cells.
Cells were exposed to these treatments, subsequently infected with
wt AAV2 and assayed 48 h later for Rep protein synthesis. Inter-
estingly, Rep proteins could be detected in small quantities in
untreated HeLa and GM847 infected cells, indicating that the rep
gene could be expressed even in the absence of helper virus co-
infection (Fig. 1). Rep proteins were similarly detected in two other
SV40-transformed cell lines, NB-E and NB-K cells (data not shown).
In contrast, there was no detectable amount of Rep proteins in
U2OS andMRC5 cells infected with wt AAV2 but left untreated with
respect to genotoxic agents (Fig. 1). The detection of Rep proteins in
the absence of treatment in virus-transformed cell lines (HeLa,
GM847, NB-E, and NB-K) but not in spontaneously transformed
(U2OS) and primary (MRC5) cells also suggested that some factors
induced upon transformation by small DNA tumor viruses might
alleviate rep gene repression. Pre-treatment of cells with genotoxic
agents induced Rep protein synthesis to different levels depending
on the agent and the cell line. In particular, MMC and IR were the
most efﬁcient whereas Eto and HU induced Rep protein synthesis in
all cell lines except MRC5 and U2OS, respectively. Altogether, this
comparative experiment reveals that wt AAV infection is differen-
tially affected depending on the cell line and the genotoxic agent.
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Previous studies had suggested that treatment of cells with
various agents including genotoxic drugs such as HU could lead to
detectable levels of wt AAV genome ampliﬁcation. To precisely
quantify this phenomenon, HeLa, U2OS, MRC5, GM847, NB-E and
NB-K cells were pre-treated with the genotoxic agents tested
above, then infected with wt AAV, followed by assessment of viral
genome replication by quantitative PCR. As a positive control, cells
were co-infected with wt HSV-1. As expected, AAV was very
efﬁciently ampliﬁed in AAV/HSV-1 co-infected cells (Fig. 2). In
contrast, only weak levels of AAV genome ampliﬁcation were
detected in cells pre-treated with the different genotoxic agents.
The highest level of AAV genome ampliﬁcation was detected in
GM847, NB-E, and NB-K cells after MMC pre-treatment. However,
this was only a ten fold increase compared to untreated AAV2-
infected cells (Fig. 2). Surprisingly, in all cell lines there was a less
than 4-fold AAV ampliﬁcation in response to HU, a drug previously
described as able to induce signiﬁcant AAV genome ampliﬁcation
(Yakobson et al., 1987; Yalkinoglu et al., 1988). Importantly, the
cell lines tested in this experiment included NB-E cells, for which
one of the reference studies had shown extensive AAV replication
after HU pre-treatment (Yakobson et al., 1987).
Effect of the multiplicity of infection on AAV DNA ampliﬁcation in
response to genotoxic treatments
Because overall levels of ampliﬁed AAV DNA remained low
even in the best conditions of induction, we next tried to
determine whether efﬁcient AAV replication requires a threshold
of input AAV genomes by increasing the MOI. This analysis was
performed with GM847 cells that had previously displayed the
most efﬁcient response to the drugs in terms of AAV genome
ampliﬁcation (Fig. 2). GM847 cells were pre-treated with Eto,
MMC, or HU, and then infected with AAV at increasing MOIs. AAV
DNA was analyzed by qPCR and Southern blot 48 h p.i. As
expected, increasing the MOI resulted in a higher absolute level
of input and replicated AAV genome (Fig. 3A). However, theFig. 2. Effect of genotoxic agents on wt AAV2 replication. HeLa, U2OS, MRC5, GM847,
103 gp/cell) and rep DNA was quantiﬁed 48 h later by qPCR. In the case of cells co-in
expressed as Rep/b-globin ratio, ﬁxed at 1 for untreated, AAV infected cells from the crelative ampliﬁcation level measured by the ratio between the
amounts of AAV DNA in treated versus untreated cells did not
increase along with the AAV MOI. Southern blot analysis revealed
the presence of AAV genomes in linear and circular monomer
double stranded forms in untreated cells. Treatment with geno-
toxic drugs resulted in the appearance of a linear dimer form but
with no evident increase over monomer forms when the MOI
increased (Fig. 3B). It was also interesting to note that even very
low levels of replication by qPCR (o10), result in visible AAV
replicative forms by Southern blot, the technique which was
previously used to monitor this phenomenon. Altogether, these
results indicate that the efﬁciency of AAV genome replication
cannot be enhanced by increasing the number of input AAV
particles and rather suggest a rapid saturation of the cellular
pathways involved in the generation of AAV ds forms.
Effect of SV40 large T antigen on AAV genome replication
The above experiments indicated a positive correlation
between the efﬁciency of AAV genome ampliﬁcation after geno-
toxic treatments and the use of cell lines transformed by SV40 or
its main transforming factor, the large T antigen (LTAg). Similarly,
most cell lines in which signiﬁcant helper-independent AAV
replication has been reported were transformed, a majority by
SV40 LTAg (Yakobson et al., 1987, 1989; Yalkinoglu et al., 1988).
The involvement of SV40 was previously suggested by the
observation that COS-7 cells, which are derived from CV-1 cells
and bear an SV40 ori– genome, efﬁciently ampliﬁed AAV genomes
in response to HU, while the SV40-free parental CV-1 cells did not
(Yakobson et al., 1987). Accordingly, LTAg was later reported as
being able to induce the synthesis of Rep proteins with, however,
no documented effect on AAV genome replication (Batchu et al.,
2001, 2002).
To further investigate the possible effect of LTAg expression on
AAV genome replication, HeLa cells were transfected with a
plasmid coding for LTAg or mock transfected and then treated
and infected as indicated above. Interestingly, transfection of
HeLa cells with a plasmid encoding LTAg, in absence of any
pre-treatment, resulted in a 4-fold ampliﬁcation of AAV2 DNANB-E or NB-K cells were pre-treated as described above, infected with AAV (MOI:
fected with wt HSV-1, analysis was performed 24 h post-infection. The data are
orresponding cell line.
Fig. 3. Effect of the AAV MOI on helper-independent AAV replication. GM847 cells were pre-treated as above and infected with AAV at the indicated MOIs. DNA was
extracted 48 h later and analyzed by qPCR (A) or Southern blot after EcoRV digestion (B). qPCR results are expressed as the Rep/b-globin ratio, ﬁxed at 1 for untreated cells
infected with the lowest AAV MOI. Note that for HSV-1/AAV co-infected samples, DNA was diluted tenfold prior to Southern blot analysis. mRF and dRF, monomer and
dimer AAV replicative forms; crm and csm, circular, relaxed or supercoiled monomeric AAV genome forms.
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were clearly detected (Fig. 4A and B). Moreover, addition of LTAg
sensitized HeLa cells to IR- and MMC-induced AAV genome
ampliﬁcation and resulted in a 5- and 20-fold increase compared
to untreated cells, respectively. Western blot analysis indicated
that LTAg does not strongly induce Rep synthesis when expressed
alone or after MMC treatment thus suggesting that its effect
might possibly be mediated by other pathways (Fig. 4C).
These results demonstrate that LTAg activities can induce a
low level of AAV genome replication in a non-permissive envir-
onment. In addition, the synergistic effect observed with some
genotoxic agents further suggests that LTAg and genotoxic treat-
ments could enhance AAV genome replication through comple-
mentary pathways.
Effect of the quality of the AAV preparation
Although the previous results established that AAV genome
replication could occur in cells producing LTAg and treated with
genotoxic agents, the ampliﬁcation factor barely exceeded 20-fold
(Fig. 4A). In contrast, previous studies on AAV helper-independent
replication, although not quantitative, suggested that higher
levels of AAV DNA replication can be reached (Yakobson et al.,
1989; Yalkinoglu et al., 1988). Additionally, several of the cell
lines in which helper-independent AAV replication has been
reported were either transformed by viruses other than SV40,spontaneously transformed or simply non-transformed, suggest-
ing that LTAg, although contributing to the effect reported in
some cell lines, is not the only factor involved. A major difference
between our experiments and those previously reported concerns
the quality of the AAV preparation used to infect the cells. Indeed,
in those studies AAV particles were produced using Ad as a helper
virus and contaminating Ad particles were inactivated by heating
the AAV preparation for 30 min at 56 1C. Such treatment results in
the nearly complete denaturation of Ad capsids without loss of
AAV infectious titer (Maheshwari et al., 2004; Russell et al., 1967).
In contrast, our studies were performed using AAV particles
produced using an Ad helper plasmid and consequently were
free of any contaminating Ad particle (Grimm et al., 1998; Xiao
et al., 1998). Thus, we hypothesized that AAV stocks previously
used to analyze AAV replication could additionally contribute to
enhance AAV replication even after heat treatment. To test this
hypothesis, HeLa cells were pre-treated with MMC and then
infected with AAV particles produced using either an Ad helper
plasmid (AAVp), or infectious Ad (Ad.dl324) and heated at 56 1C
for 30 min to inactivate infectious Ad particles (AAVAdy). An
additional control condition involved the use of an AAVAd stock
that was not heat treated. Measure of infectious Ad particles in
the AAVAd preparation indicated a level of contamination of
8105 pfu/mL that became undetectable after heat inactivation
(o2102 pfu/mL). In addition, to monitor the potential effect of
LTAg, cells were also transfected with plasmids encoding either
Fig. 4. Effect of LTAg on helper-independent AAV replication. HeLa cells were transfected with a plasmid coding for LTAg or eGFP, then either pre-treated as above and
infected with AAV (MOI: 103 gp/cell) and harvested 48 h later, or co-infected with wt HSV-1 (MOI: 5 pfu/cell) and AAV (MOI: 103 part./cell) and harvested 24 h later. DNA
was extracted and analyzed by qPCR (A) or Southern blot (B). ss, single-stranded AAV genomes; mRF and dRF, monomer and dimer AAV replicative forms; crm, circular,
relaxed monomeric AAV genome forms. Note that the blot was overexposed to detect the low level of replicative forms in cells treated with genotoxic drugs. (C) Extracts
from MMC treated and LTAg transfected cells were analyzed by Western blot using an anti Rep antibody. Membranes were then stripped and re-probed with an anti-
tubulin antibody.
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qPCR and Southern blot. As expected, replication of the AAV
genome could be detected in cells infected with AAVAd even in the
absence of any additional treatment (Fig. 5A and B). In contrast it
was undetectable both by qPCR and Southern blot in cells infected
with AAVAdy thus indicating that heat-inactivation had restored
AAV replication to a level similar to that observed for AAVp.
Expression of LTAg and/or MMC pre-treatment increased AAV
genome levels relative to controls for all AAV stocks. However,
AAVAdy-infected cells responded nearly four times better to MMC
than those infected with AAVp (Fig. 5A). A signiﬁcant difference in
the ampliﬁcation ratios between AAVp- and AAVAdy-infected cells
was also observed in cells expressing LTAg with MMC pretreat-
ment. To further determine the effect of these treatments on the
life cycle of AAV and particularly on particle formation the
samples displaying the highest level of AAV replication were
analyzed by Western blot to detect VP proteins (Fig. 5C). No VP
proteins were detected in cells exposed to AAVp or AAVAdy in the
absence of any other treatment, thus conﬁrming that the life cycle
of AAV is limited to second strand synthesis and rep gene
expression in these cells. In contrast VP proteins were detected
in cells infected with AAVAd. Addition of LTAg followed by pre-treatment with MMC induced the synthesis of VP in all condi-
tions, further suggesting that low levels of infectious AAV parti-
cles can be produced.
Altogether, these data suggested that the quality of the AAV
preparation is an additional factor that together with genotoxic
stress and/or viral helper factors such as LTAg may contribute to
create an environment permissive for the AAV life cycle.Discussion
In this study, we set out to determine if, as previously reported
and commonly accepted, AAV can replicate in the absence of a co-
infecting helper virus in cells treated with genotoxic agents
(Yakobson et al., 1987, 1989; Yalkinoglu et al., 1988). Under-
standing the capacity of AAV to replicate in absence of helper
virus is important not only from a theoretical point of view but
also for the biology of rAAV vectors. Indeed, since latent AAV is
frequently recovered from human samples (Gao et al., 2004;
Schnepp et al., 2005, 2009), it is likely that, after in vivo injection
of rAAV vectors in human tissues, a situation can arise where a
cell bears both rAAV vector and wt AAV genomes. In these
Fig. 5. Effect of the quality of the AAV preparation on helper-independent AAV replication. HeLa cells were transfected with a plasmid coding for LTAg or eGFP, then pre-
treated as above and infected with AAV particles (MOI: 103 part./cell) from three different origins: AAV produced using plasmid-cloned Ad helper activities (AAVp); AAV
produced using Ad.dl324-infected 293 cells (AAVAd); AAV produced using Ad.dl324-infected 293 cells and incubated for 30 min at 56 1C (AAVAd,y). The cells were harvested
48 h after infection. Untreated, wt HSV-1 and AAV co-infected cells were harvested 24 h p.i. DNA was extracted and analyzed by qPCR (A) and Southern blot after Pst I
digestion (B). This enzyme cuts twice within the rep gene and generates a 1.4 kb band. For HSV-1/AAV co-infected samples, DNA was diluted tenfold prior to Southern blot
analysis. (C) Detection of VP proteins by Western blot. Extracts from treated cells were analyzed using the anti VP B1 antibody.
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potentially lead to unwanted and uncontrolled replication and
spreading of rAAV particles.
Initial experiments using doses and protocols similar to older
studies reporting this phenomenon conﬁrmed that the treatments
assayed could stimulate rAAV transduction in a variety of cell lines
(data not shown). Additional experiments showed that all treat-
ments could induce or increase Rep proteins synthesis in absence
of helper virus although at different levels among the tested cell
lines. However, all the treatments including HU induced only very
weak levels of AAV genome ampliﬁcation, never exceeding a
10-fold increase compared to untreated cells. Southern blotanalysis conﬁrmed that the observed increase in AAV DNA levels
resulted from true AAV genome replication. The inability of all
these treatments, contrary to what had been previously reported,
to induce robust AAV replication prompted us to analyze the
dependence of this phenomenon on other extrinsic factors.
Comparison with reference studies was complicated because the
AAV MOIs were expressed on the basis of infectious units that were
measured using less sensitive assays such as immune-ﬂuorescence
analysis of infected cells, whereas in our assays the MOI was deﬁned
on the basis of the number of genome-containing particles measured
by qPCR. Therefore, we tested the effect of a range of AAV MOIs on
the induction of helper independent replication. Surprisingly, a
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genome ampliﬁcation was not found, further suggesting that this
phenomenon could be easily saturated.
Because SV40-transformed cell lines proved the most suscep-
tible to AAV helper-independent replication, we then examined the
role of SV40 LTAg in this phenomenon. For these studies we used
the Hela cell line which is transformed by HPV. This choice was
guided by several considerations. First, of the three HPV helper
factors (E1, E2 and E6), only E6 is present in its full length in HeLa
cells. (Inagaki et al., 1988; Schwarz et al., 1985). Importantly, the
only remaining HPV gene, E6, was recently shown to be insufﬁcient
for full AAV replication in HEK-293 cells (Cao et al., 2012). Thus,
HeLa cells do not express the full complement of HPV helper
factors. Second, according to our results this cell line was poorly
responsive to the variety of treatments used in this study despite
being efﬁciently transduced by AAV thus constituting a goodmodel
to evaluate the cumulative effects of other factors (Figs. 2 and 3).
Last but not least, these cells can be efﬁciently transfected thus
facilitating the analysis of the effect of LTAg. Our analyses showed
that LTAg allowed a limited AAV genome replication despite a
moderate effect on rep gene expression. These results indicate that
LTAg, although not sufﬁcient per se, may contribute to helper
independent AAV replication. Further studies conducted in primary
cells will likely indicate if transformation, whether virally induced
or not, can also contribute to this phenomenon.
Finally, we observed that the quality of the AAV preparation and
in particular the presence of Ad-derived contaminants also con-
tributed to induce AAV genome replication. Indeed, heat treatment
of AAV particles produced using infectious Ad (Ad.dl324) resulted in
a 4-fold higher level of AAV replication when added to cells
additionally pretreated with MMC and producing LTAg as compared
to cells infected with AAV particles produced in the absence of
infectious Ad. It is likely that this phenomenon results from a
residual undetectable level of infectious Ad particles or factors
which, even if unable per se to induce AAV replication, can
synergistically enhance it in the presence of other factors such as
LTAg and/or genotoxic treatments. Importantly, the Ad strain used
in our study was the replication defective Ad.dl324 strain, which
lacks E1, one of the main AAV helper factors. In contrast, in
reference publications, AAV stocks were produced using wt Ad2
(Yakobson et al., 1989; Yalkinoglu et al., 1988), and, thus, the
potential effect of inactivated Ad particles with residual helper
activity could have been greater than the one observed in our
present work. It is also possible that, besides residual infectious
adenoviral particles, other viral or cellular factors co-puriﬁed with
AAV particles may contribute to this effect. A detailed comparison
of Ad and cellular contaminants present in both types of AAV
preparation should be performed in order to answer this question.
Altogether, our results indicate that in vitro, DNA damage and/or
cell cycle alterations result in very limited helper independent AAV
replication, and that induction beyond background levels depends
on the synergistic contribution of several extrinsic factors linked to
the origin of the cell line and the quality of the AAV preparation.
These results further support the notion that helper independent
AAV replication cannot occur at signiﬁcant levels in vivo.Materials and methods
Cell lines and virus strains
HeLa (HPV18-transformed human cervical epithelial cells),
U2OS (spontaneously transformed human osteosarcoma cells),
GM-847 (SV40-transformed human skin ﬁbroblasts), NB-E and
their derivative NB-K (SV40-transformed human newborn kidney
cells, kindly provided by J. Rommelaere), and HEK-293 (Ad5-transformed human embryonic kidney cells) were maintained in
Dulbecco’s modiﬁed Eagle’s medium (DMEM, Sigma) supplemen-
ted with 10% fetal calf serum (FCS, HyClone) and 1% penicillin–
streptomycin (PS, 5000 U/mL, Invitrogen).
Wild type AAV2 (AAV) was produced by co-transfecting HEK-
293 cells with plasmids pXX6 and pAV2. Alternatively, an E1- and
E3-deleted adenovirus mutant dl324 (Ad.dl324) was used to
provide the helper activities. AAVtR particles contained a modiﬁed
AAV2 genome, with a deletion of the cap gene and an N-terminal
fusion of the rep open reading frame with a TAP tag. These
particles were produced by co-transfection of 293 cells with the
AAVtR plasmid, the pXX6 helper construct and a plasmid expres-
sing the cap gene (pEF1a-cap). Wild type AAV and AAVtR particles
were puriﬁed using either iodixanol or CsCl density gradients, and
titrated by qPCR to measure the number of genome-containing
particles (gp). AAV2/2CMVeGFP particles were produced by
cotransfection of 293 cells with pAAVCMVeGFP and pDG plasmids
and puriﬁed and titrated as described above. The HSV-1 viruses
used in the study were wt HSV-1 (17 synþ) provided by D. Coen
(Harvard University, Boston, MA, USA). HSV stocks were produced
and titrated on Vero cells (provided by C. Hwang, SUNY Health
Science Center, Syracuse, NY, USA) by standard procedures.
Treatments and infection of cells
For the analysis of rAAV transduction or wt AAV replication, cells
were seeded in 6-well plates at a density of 5105 cells per well. One
day later, cells were incubated with DMEM/10% FCS/1% PS containing
either 1 mM Hydroxyurea (HU, Sigma), 5 mM mitomycine C (MMC,
Sigma) or 10 mM etoposide (Eto, Sigma) for 20 h. The cells were then
washed in DMEM/10% FCS/1% PS and infected 2–4 h later with wt
AAV-2 at a multiplicity of infection (MOI) of 103 particles/cell unless
otherwise indicated. Alternatively, the cells were subjected to a dose
of 40 Gy g radiation (source: 137Cs) and infected as above. Positive
control cells were simultaneously co-infected with wt HSV-1 at an
MOI of 5 plaque forming units (pfu)/cell and AAV at anMOI of 103 gp/
cell. Times post-infection (p.i.) were calculated from the time of
addition of the virus. When indicated, cells were additionally trans-
fected with 0.25 pmol of SV40 LTAg expressing plasmid (pLOX-Ttag-
iresTK, kindly provided by D. Trono) using a standard calcium
phosphate transfection protocol. Control cells were transfected with
0.25 pmol of pEGFP-N1 (Clontech).
Western blot analysis
The cells were collected, washed in PBS and lysed with RIPA
buffer (20 mM Tris–HCl pH 7.4, 50 mM NaCl, 1 mM EDTA, 0.5%
Nonidet P-40, 0.5% deoxycholate, and 0.5% SDS) in the presence of
a cocktail of protease inhibitors (Roche). Proteins were loaded on
10% SDS polyacrylamide gels and then transferred to nitrocellu-
lose membranes (GE Healthcare). After saturation, the mem-
branes were incubated overnight at 4 1C with the appropriate
antibody diluted in blocking buffer. The anti-Rep 303.9 mouse
monoclonal antibody was used at a 1/20 dilution. The anti-
tubulin (T5168, Sigma) mouse monoclonal antibody was used at
a 1/2000 dilution. After PBS washes, a horseradish peroxidase-
conjugated anti-mouse antibody (Dako) was applied to the
membranes at a 1/20,000 dilution for 1 h at room temperature
(RT). Finally, the membranes were incubated for 5 min with the
enhanced chemiluminescence reagent (West Dura, Pierce) and
exposed to an autoradiography ﬁlm.
Southern blot analysis
One to 10 mg of total DNA were digested with EcoRV or PstI for
6 h at 37 1C, run on a 1% agarose gel and transferred to a Hybond
A. Nicolas et al. / Virology 432 (2012) 1–98Nþmembrane (GE Healthcare) by capillarity. The membrane was
then hybridized overnight to a digoxigenin (DIG)-labeled probe in
EasyHyb solution (Roche). DIG-labeled rep probes were synthe-
sized using the DIG PCR Probe Synthesis kit (Roche) following the
manufacturer’s instructions. Probe size and DIG incorporation
were checked by agarose gel electrophoresis (1%). Two rep probes
were synthesized. The primers used were rep1-F (50-cgagattgt-
gattaaggtcc-30)/rep1-R (50-caggcgcttaaatactgttcc-30), rep2-F (50-
ccgcatattggggatcgtac-30)/rep2-R. After overnight hybridization,
the membrane was processed following the manufacturer’s
instructions, incubated for 5 min at RT with CDPstar (Roche),
and then exposed to an autoradiography ﬁlm.
Quantitative PCR
Primers used for the qPCR reaction were Rep-F (50-gcaagaccg-
gatgttcaaat-30) and Rep-R (50-cctcaaccacgtgatccttt-30) for rep
gene ampliﬁcation; b-globin-F (50-cccttggacccagaggttct-30) and
b-globin-R (50-cgagcactttcttgccatga-30) or ChrX-F (50-gacagtcagccg-
catcttctt-30) and ChrX-R (50agttaaaagcagccctggtga-30) for cellular
genomic b-globin or chromosome X DNA ampliﬁcation, respec-
tively. For initial analyses (Figs. 2 and 3), reactions were performed
as previously described (Alazard-Dany et al., 2009) and data were
expressed as a Rep/Chr.X ratio which was ﬁxed at 1 for untreated,
AAV genome-positive cells from the corresponding cell line. In
subsequent experiments (Figs. 4 and 5), 10 mL of 2X FastStart
Universal SYBER Green Master (Rox) (Roche) was used in a ﬁnal
volume of 20 mL (in a 96 well plate, Eurogentec). Each primer was
used at a ﬁnal concentration of 300 nM. Approximately 12.5 ng of
DNA was analyzed. Reactions were always set up at least in
duplicate. Each qPCR was performed as follows: 10 min hot-start
denaturation at 95 1C and 40 ampliﬁcation cycles (15 s at 95 1C, 40 s
at 60 1C). The melting temperature of the ﬁnal double-stranded
DNA products was determined by gradual heating from 60 1C to
95 1C over 20 min. Reactions were performed with the StepOnePlus
Real-Time PCR System (Applied Biosystems) and associated soft-
ware. Absolute amounts of Rep and b-globin amplicons in arbitrary
units were determined using serial dilutions of genomic DNA from
uninfected HeLaAAVtCR cells (Alazard-Dany et al., 2009) as a
standard. The data are expressed as Rep/b-globin ratio, ﬁxed at
1 for untreated, AAV infected cells from the corresponding cell line.
The data presented in Figs. 2–5 indicate the mean obtained from
three independent measures of one representative experiment with
error bars corresponding to the standard error.Acknowledgments
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